Stock GTBP GT BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

GT Biopharma, Inc. Stock Euronext Paris

Equities

GTBP

US36254L3087

Pharmaceuticals

Market Closed - Euronext Paris
Other stock markets
 05:30:03 2020-12-24 am EST 		5-day change 1st Jan Change
0.55 EUR -86.52% Intraday chart for GT Biopharma, Inc. -96.67% -99.80%
Jun. 27 GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650 MT
Jun. 27 GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study DJ

Financials

Sales 2022 - Sales 2023 - Capitalization 10.56M 9.68M
Net income 2022 -20M -18.34M Net income 2023 -7M -6.42M EV / Sales 2022 -
Net cash position 2022 16.33M 14.98M Net cash position 2023 13.91M 12.76M EV / Sales 2023 -
P/E ratio 2022
-1.35 x
P/E ratio 2023
-1.36 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 89.34%
More Fundamentals * Assessed data

Chart GT Biopharma, Inc.

Dynamic Chart

Latest news about GT Biopharma, Inc.

GT Biopharma Says FDA Clears Investigational New Drug Application for Cancer Drug GTB-3650 MT
GT Biopharma Shares Rise on FDA Clearance for Cancer-Drug Study DJ
GT Biopharma, Inc. Announces FDA Clearance of Investigational New Drug Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia CI
GT Biopharma, Inc. Announces CFO Changes CI
Top Midday Decliners MT
GT Biopharma Prices $3.2 Million Registered Direct Offering of Shares, Concurrent Private Placement of Warrants MT
Top Premarket Gainers MT
GT Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall MT
GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia CI
GT Biopharma, Inc. Presents Positive Preclinical Data for GTB-5550, a Novel TriKE(R) Molecule for Targeted Prostate Cancer Treatment During the Society for Immunotherapy of Cancer 2023 Annual Meeting CI
GT Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
GT Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
GT Biopharma, Inc.(NasdaqCM:GTBP) dropped from Russell Microcap Index CI
More news

Analyst Recommendations on GT Biopharma, Inc.

EF Hutton Starts GT Biopharma at Hold With $2 Price Target MT
HC Wainwright Adjusts Price Target on GT Biopharma to $5 From $25, Reiterates Buy Rating MT
Roth Capital Cuts GT Biopharma to Neutral From Buy, Price Target to $3 From $9 MT
B. Riley Lowers GT Biopharma's Price Target to $18 from $26 After Revising Cost Capital Assumptions, Keeps Buy Rating MT
GT BIOPHARMA : B. Riley Raises GT Biopharma's PT to $26 from $21, Notes Steady Progress of Dose-Escalation Trial of Lead Asset GTB-3550; Keeps Buy Rating MT
More recommendations

Press releases GT Biopharma, Inc.

GT BIOPHARMA ANNOUNCES FDA CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR GTB-3650, AN NK CELL ENGAGER FOR TREATMENT OF CD33+ LEUKEMIA AQ
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-3650, an NK Cell Engager for Treatment of CD33+ Leukemia AQ
GT Biopharma, Inc. Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules AQ
GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update AQ
GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results AQ
More press releases

News in other languages on GT Biopharma, Inc.

Caterpillar deja París, el cacao está menos caliente
Le bric-à-brac de Zonebourse : Caterpillar quitte Paris, le cacao est moins chaud
More news

Quotes and Performance

1 day-86.52%
1 week-96.67%
Current month-96.67%
1 month-96.67%
3 months-94.12%
6 months-99.80%
Current year-99.80%
More quotes

Highs and lows

1 week
9.35
Extreme 9.35
16.50
1 month
9.35
Extreme 9.35
16.50
Current year
9.35
Extreme 9.35
280.50
1 year
9.35
Extreme 9.35
280.50
3 years
9.35
Extreme 9.35
280.50
5 years
9.35
Extreme 9.35
280.50
10 years
9.35
Extreme 9.35
1 000 000.00
More quotes

Managers and Directors - GT Biopharma, Inc.

Managers TitleAgeSince
Michael Breen CEO
 Chief Executive Officer 61 21-01-12
Jeffrey Miller PRN
 Corporate Officer/Principal - 22-12-13
Members of the board TitleAgeSince
Charles Casamento BRD
 Director/Board Member 78 23-04-30
Bruce Wendel BRD
 Director/Board Member 70 20-11-10
Rajesh Shrotriya BRD
 Director/Board Member 79 21-01-12
More insiders

Quotes

Date Price Change
24-07-12 16.5 -.--%
24-07-11 16.5 -.--%
24-07-10 16.5 -.--%
24-07-09 16.5 -.--%
24-07-08 16.5 -.--%

Real-time Euronext Paris, December 24, 2020 at 05:30 am EST

More quotes

Company Profile

GT Biopharma, Inc. specializes in the research and development of therapeutic products used primarily for the treatment of cancer and disorders of the central nervous system. The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).
Sector
Pharmaceuticals
Calendar
2024-08-06 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+62.66% 854B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.42% 636B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.37% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.16% 324B
ABBVIE INC. Stock AbbVie Inc.
+9.87% 301B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.66% 247B
ROCHE HOLDING AG Stock Roche Holding AG
+4.21% 230B
NOVARTIS AG Stock Novartis AG
+17.90% 228B
AMGEN INC. Stock Amgen Inc.
+14.86% 177B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GTBP Stock
  4. GTBP Stock